Medikament Pharma: A Specialized API Manufacturer Developing Innovative Pharma Solutions To Improve Patient Health

While the global API mar­ket is set to grow at a 5.85 percent CAGR, the Indian API market is projected to grow faster at 7.7 percent through 2030 and the country is in­creasingly being recognized as a global hub for high-quality, cost-effective API production.

Several factors are accel­erating this growth, driven by a push for self-reliance, rising therapeutic de­mand, an aging population, and post- COVID supply chain rebalancing for APIs.

International pharma companies are looking to diversify their API suppli­ers, and India is emerging as a strategic choice. This is where high-quality API manufacturers come into the picture.

Leading this momentum is Medika­ment Pharma, a specialized manufac­turer of high-quality APIs and Novel Chemical Entities (NCEs) for regulated and semi-regulated markets with a vi­sion to lead it, by delivering critical raw materials that are safe, scalable, and sustainable. With a strong foundation in GMP compliance, vertical integration, and process optimization, the company is known for its reliability and scientific rigor.

Medikament Pharma's facility in Saykha GIDC, Gujarat, is strategically located in one of India’s key pharma­ceutical zones, enhancing its access to global supply chains and regulatory frameworks.

Quality-by-design Approach

“Since inception, we have followed a "quality-by-design" (QbD) approach. Our QA strategies are built on rigorous raw material screening, validated an­alytical methods and instrument cal­ibration protocols, frequent internal audits, SOP-driven operations across every stage of production, and full traceability through electronic batch records (eBMR) and LIMS systems”, af­firms Murtuza Vasanwala, Founder & Managing Director, Medikament Phar­ma.

Murtuza’s academic journey spans a Bachelor of Pharmacy and a Master’s in Pharmaceutical Sciences, comple­mented by a Diploma in NHS and an ILM qualification in Management.

“

Medikament Pharma aligns R&D strategy based on therapeutic relevance, global demand forecasts, and IP space

---

Founder Murtuza Vasanwala also reflects on how the company is turning regulatory rigor into a competitive ad­vantage that shapes its trajectory. “Me­dikament Pharma aligns R&D strategy based on therapeutic relevance, global demand forecasts, and IP space.

Each therapeutic area comprises a dedicat­ed team of scientists working on route scouting and impurity profiling. Me­dikament Pharma has invested in green chemistry, continuous process devel­opment, and kilo labs scaling to reduce time-to-market while ensuring compli­ance. Its R&D team works closely with customers to co-develop and customize molecules based on formulation and bioavailability needs”, affirms Murtuza.

Boosting Manufacturing Efficiency & Quality Control

Medikament Pharma's Gujarat plant with dedicated divisions and clean rooms enhance manufacturing efficiency and quality control. Medikament Pharma differentiates itself through a focused product portfolio with deep specialization in select APIs, rapid development, and client-centric customization, regulatory-led, not just cost-driven, a highly integrated setup from R&D, to commercial manufacturing, all under one roof, and strong supply chain reliability and technical transparency with partners.

The Journey so far & Path Ahead!

Since its establishment in 2016, Me­dikament Pharma's journey has been marked by organic growth and strate­gic expansion. What began with a mod­est customer base in India has evolved into a globally trusted name in API manufacturing, with a strong export footprint. Over the years, the company has increased its production capaci­ty, significantly strengthened its R&D, regulatory, and quality teams, enduring partnerships with formulators, con­tract manufacturers (CMOs), and inno­vators across the global landscape.

“Our roadmap includes dedicating a new block to APIs, filing Drug Master Files (DMFs) for key regulated markets, exploring green chemistry routes for molecules, and expanding our portfo­lio in complex intermediates and NCEs. We are also enhancing our digital infra­structure for better process control and traceability”, says Murtuza Vasanwala.

Looking ahead, Medikament Phar­ma is poised to disrupt the market with its upcoming biosimilars and oral insu­lin API pipeline, slated for 2026.

“Although not be the largest in scale, we operate with the agility, quality, and mindset of a global player. Medikament Pharma is more than a supplier, we are a science-driven partner committed to quality, innovation, and health”, con­cludes Murtuza Vasanwala.